Native and Non-Native aggregation pathways of antibodies anticipated by cold-accelerated studies
European Journal of Pharmaceutics and Biopharmaceutics · 2023
DOI: 10.1016/j.ejpb.2023.10.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Miguel A Rodrigues und 7 weiteren Autor:innen. Beteiligte Einrichtung: SmartFreeZ, Ed. Inovação II, Incubadora Taguspark, Porto Salvo, Portugal; CQE, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal. …. Hauptthemen laut MEDLINE: Cold Temperature, Antibodies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Assessment of cold stability is essential for manufacture and commercialization of biotherapeutics. Storage stability is often estimated by measuring accelerated rates at elevated temperature and using mathematical models (as the Arrhenius equation). Although, this strategy often leads to an underestimation of protein aggregation during storage. In this work, we measured the aggregation rates of two antibodies in a broad temperature range (from 60 °C to -25 °C), using an isochoric cooling method to prevent freezing of the formulations below 0 °C. Both antibodies evidenced increasing aggregation rates when approaching extreme temperatures, because of hot and cold denaturation. This behavior was modelled using Arrhenius and Gibbs-Helmholtz equations, which enabled to deconvolute the contribution of unfolding from the protein association kinetics. This approach made possible to model the aggregation rates at refrigeration temperature (5 °C) in a relatively short timeframe (1-2 weeks) and using standard characterization techniques (SEC-HPLC and DLS).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SmartFreeZ, Ed. Inovação II, Incubadora Taguspark, Porto Salvo, Portugal; CQE, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal. Electronic address: miguelrodrigues@tecnico.ulisboa.pt.
- SmartFreeZ, Ed. Inovação II, Incubadora Taguspark, Porto Salvo, Portugal.
- SmartFreeZ, Ed. Inovação II, Incubadora Taguspark, Porto Salvo, Portugal; CQE, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal.
- Biologics Drug Product Development, Sanofi, Framingham, MA, USA.
- Biologics Drug Product Development, Sanofi, Framingham, MA, USA; Current address: Commercial Drug Product Manufacturing Science and Technology, Moderna, Norwood, MA, USA.
- Biologics Drug Product Development, Sanofi, Vitry-sur-Seine, France.
Förderung
- Sanofi
Zitieren
APA
Rodrigues, M. A., Duarte, A., Geraldes, V., Kingsbury, J. S., Sanket, P., Filipe, V., Nakach, M., & Authelin, J. R. (2023). Native and Non-Native aggregation pathways of antibodies anticipated by cold-accelerated studies. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.10.009
Vancouver
Rodrigues MA, Duarte A, Geraldes V, Kingsbury JS, Sanket P, Filipe V, et al. Native and Non-Native aggregation pathways of antibodies anticipated by cold-accelerated studies. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.10.009
BibTeX
@article{Rodrigues2023,
author = {Rodrigues, Miguel A and Duarte, Andreia and Geraldes, Vitor and Kingsbury, Jonathan S and Sanket, Patke and Filipe, Vasco and Nakach, Mostafa and Authelin, Jean-Rene},
title = {Native and Non-Native aggregation pathways of antibodies anticipated by cold-accelerated studies},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
doi = {10.1016/j.ejpb.2023.10.009}
}
EUVIMED